Sun Pharma signs Akshay Kumar as brand ambassador for Revital H

New Delhi: Sun Pharma signs Akshay Kumar as brand ambassador for Revital H Drug major Sun Pharmaceutical Industries Monday said Sun Pharma Consumer Healthcare has signed Bollywood star Akshay Kumar as the brand ambassador of health supplement Revital H.

“In Akshay Kumar, we have found a perfect ambassador who is not only physically fit but also exudes great energy at all times – attributes that define Revital H at its core,” Sun Pharma CEO – India, Emerging Markets and Consumer Healthcare Kal Sundaram said.

Shares of Sun Pharmaceutical Industries on Monday were trading at Rs 569.45 per scrip in the afternoon trade on BSE, up 1.97 per cent from its previous close.

  • Related Posts

    • Pharma
    • June 19, 2025
    • 97 views
    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    This small-cap pharma stock, engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets, rose over 2% in today’s trade after receiving approval for its product…

    • Pharma
    • June 19, 2025
    • 123 views
    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    ED raids three pharma units in Baddi, Nalagarh

    ED raids three pharma units in Baddi, Nalagarh

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations